| Name | Title | Contact Details |
|---|
DripDrop is an oral rehydration therapy, based in San Francisco, California.
SCA`s vision is to be the partner of choice for physicians, hospitals, and health systems in developing and operating ambulatory surgery centers and surgical hospitals across the country and in enhancing hospital-based surgical departments. SCA owns and/or provides management services to 210 ambulatory surgery centers, surgical hospitals, and hospital surgery departments, in partnership with approximately 7,500 physicians and in affiliation with 110 health systems. SCA`s clinical systems, service line growth strategies, benchmarking processes, and efficiency programs create measurable advantage for surgical facilities – clinically, operationally, and financially.
Araceli Biosciences is a company that develops scientific instrumentation to improve outcomes in tissue and cell based biomarker discovery, drug discovery and drug development.
Hinge Health is pioneering the world`s most patient-centered Digital Musculoskeletal (MSK) Clinic™. Four in five employers and 90% of health plans with a digital MSK solution have chosen Hinge Health. Hinge Health reduces MSK pain, opioid use, and surgeries by pairing advanced wearable sensors and computer vision technology with a comprehensive Clinical Care Team with doctors of physical therapy, physicians, board-certified health coaches, and more. Hinge Health`s Digital MSK Clinic is connected with 750,000+ in-person providers and enables real-time interventions for proven medical claims reduction. Available to millions of members, Hinge Health is the #1 Digital MSK Clinic with 500+ health plans and employers customers, including Boeing, Salesforce, and US Foods. Hinge Health has raised $826M to date with offices across San Francisco, Austin, Chicago, Denver, Minneapolis, Portland, Seattle and more.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.